Patents Assigned to Rubicon Research Private Limited
-
Patent number: 11147767Abstract: The present invention relates to gastroretentive formulations and to processes for preparation of the same. Particularly, the invention relates to gastroretentive dosage forms comprising at least one swelling agent and at least one swelling retardant.Type: GrantFiled: February 25, 2020Date of Patent: October 19, 2021Assignee: RUBICON RESEARCH PRIVATE LIMITEDInventor: Pratibha Pilgaonkar
-
Patent number: 10806685Abstract: The present invention relates to oral care compositions and to method of maintaining oral health. The oral care composition of the present invention comprises at least one carbon dioxide source, at least one acid source, at least one abrasive and one or more pharmaceutically acceptable excipients.Type: GrantFiled: September 28, 2012Date of Patent: October 20, 2020Assignee: RUBICON RESEARCH PRIVATE LIMITEDInventors: Pratibha Sudhir Pilgaonkar, Maharukh Tehmasp Rustomjee, Anilkumar Surendrakumar Gandhi
-
Patent number: 10463623Abstract: The present invention provides a composition exhibiting delayed transit through the gastrointestinal tract comprising one or more active agents, fenugreek fiber and at least one pharmaceutically acceptable excipient. The present invention further relates to gastroretentive dosage forms comprising fenugreek fibers.Type: GrantFiled: September 22, 2009Date of Patent: November 5, 2019Assignee: RUBICON RESEARCH PRIVATE LIMITEDInventors: Pratibha Sudhir Pilgaonkar, Maharukh Tehmasp Rustomjee, Anilkumar Surendrakumar Gandhi, Rupali Kedar Suvarnapathaki
-
Patent number: 10391060Abstract: The present invention provides particulate delivery systems comprising plurality of particles comprising fenugreek gum and at least one pharmaceutically acceptable excipient. The particulate delivery systems of the present invention are used for the delivery of therapeutic, immunologic or diagnostic agents, and the like.Type: GrantFiled: August 5, 2016Date of Patent: August 27, 2019Assignee: RUBICON RESEARCH PRIVATE LIMITEDInventors: Pratibha Pilgaonkar, Anilkumar Gandhi, Paras Jain
-
Patent number: 10286024Abstract: An excipient from Trigonella foenum-graceum seeds and a process for preparation thereof is disclosed. The excipient obtained from Trigonella foenum-graceum seeds, comprising insoluble and soluble dietary fibers can be used in various pharmaceutical or cosmetic compositions and food, nutritional or dietary preparations.Type: GrantFiled: April 6, 2011Date of Patent: May 14, 2019Assignee: RUBICON RESEARCH PRIVATE LIMITEDInventors: Pratibha Sudhir Pilgaonkar, Maharukh Tehmasp Rustomjee, Anilkumar Surendrakumar Gandhi
-
Patent number: 10010529Abstract: The present invention provides extended release pharmaceutical formulations of valsartan with controlled impurity levels. Particularly, the present invention provides extended release valsartan formulation which is substantially free of valsartan R-isomer impurity.Type: GrantFiled: June 26, 2017Date of Patent: July 3, 2018Assignees: Ezra Pharma LLC, Rubicon Research Private LimitedInventors: Joseph A. Fix, Shirish A. Shah, Pratibha S. Pilgaonkar, Anilkumar S. Gandhi
-
Publication number: 20170326066Abstract: The present invention relates to methods and composition for treatment of hypertension. Particularly the present invention provides a method of treating hypertension comprising orally administering once a day to a human patient in need thereof the compound valsartan in an extended release dosage form, wherein said extended release valsartan dosage form reduces mean systolic and diastolic blood pressure in a patient during a time period of about 20 hours to about 24 hours after administration to a greater extent than an immediate release formulation of valsartan.Type: ApplicationFiled: May 13, 2016Publication date: November 16, 2017Applicants: Ezra Pharma LLC, Rubicon Research Private LimitedInventors: Joseph A. Fix, Shirish A. Shah, Pratibha S. Pilgaonkar, Anilkumar S. Gandhi
-
Publication number: 20170326065Abstract: The present invention relates to methods for treatment of cardiovascular conditions selected from high blood pressure, heart failure, or heart attack. The present invention further relates to a method of treating cardiovascular conditions comprising orally administering once a day to a human subject in need thereof the compound valsartan in an extended release dosage form, wherein the ratio of mean plasma concentration of valsartan provided by the extended release dosage form to the mean plasma concentration of valsartan provided by an immediate release dosage form of valsartan over 8 hour to 24 hour period after administration is greater than 1 in a single dose human pharmacokinetic study.Type: ApplicationFiled: May 13, 2016Publication date: November 16, 2017Applicants: Ezra Pharma LLC, Rubicon Research Private LimitedInventors: Joseph A. Fix, Shirish A. Shah, Pratibha S. Pilgaonkar, Anilkumar S. Gandhi
-
Publication number: 20170290805Abstract: The present invention provides extended release pharmaceutical formulations of valsartan with controlled impurity levels. Particularly, the present invention provides extended release valsartan formulation which is substantially free of valsartan R-isomer impurity.Type: ApplicationFiled: June 26, 2017Publication date: October 12, 2017Applicants: Ezra Pharma LLC, Rubicon Research Private LimitedInventors: Joseph A. Fix, Shirish A. Shah, Pratibha S. Pilgaonkar, Anilkumar S. Gandhi
-
Publication number: 20170273946Abstract: The present invention relates to coated extended release pharmaceutical formulations of valsartan comprising a core comprising valsartan and at least one coating layer over the core. The present invention further relates to extended release pharmaceutical formulations comprising (a) a core comprising valsartan and at least one hydrophilic swelling polymer and (b) at least one coating layer over the core wherein the coating layer in contact with the core is applied from an organic solvent based system.Type: ApplicationFiled: June 12, 2017Publication date: September 28, 2017Applicants: Ezra Pharma LLC, Rubicon Research Private LimitedInventors: Joseph A. Fix, Shirish A. Shah, Pratibha S. Pilgaonkar, Anilkumar S. Gandhi
-
Patent number: 9687475Abstract: The present invention provides extended release pharmaceutical formulations of valsartan with controlled impurity levels. Particularly, the present invention provides extended release valsartan formulation which is substantially free of valsartan R-isomer impurity.Type: GrantFiled: March 24, 2016Date of Patent: June 27, 2017Assignees: Ezra Pharma LLC, Rubicon Research Private LimitedInventors: Joseph A. Fix, Shirish A. Shah, Pratibha S. Pilgaonkar, Anilkumar S. Gandhi
-
Patent number: 9675585Abstract: The present invention relates to coated extended release pharmaceutical formulations of valsartan comprising a core comprising valsartan and at least one coating layer over the core. The present invention further relates to extended release pharmaceutical formulations comprising (a) a core comprising valsartan and at least one hydrophilic swelling polymer and (b) at least one coating layer over the core wherein the coating layer in contact with the core is applied from an organic solvent based system.Type: GrantFiled: March 24, 2016Date of Patent: June 13, 2017Assignees: Ezra Pharma, Rubicon Research Private LimitedInventors: Joseph A. Fix, Shirish A. Shah, Pratibha S. Pilgaonkar, Anilkumar S. Gandhi
-
Patent number: 9629915Abstract: The novel sustained release dosage form comprising an active agent and a combination of a non-swelling pH dependent release retardant and a non swelling pH independent release retardant polymer which provides pH-independent drug release for a considerable period of time after administration.Type: GrantFiled: December 5, 2014Date of Patent: April 25, 2017Assignee: Rubicon Research Private LimitedInventors: Pratibha S Pilgaonkar, Maharukh T Rustomjee, Anilkumar S Gandhi, Paras R Jain, Atul A Kelkar
-
Patent number: 9198862Abstract: Disclosed herein is a dispersible tablet composition including a pharmacologically active ingredient and at least one excipient that reduces the sedimentation rate of the active ingredient and a process for preparing the same.Type: GrantFiled: July 24, 2006Date of Patent: December 1, 2015Assignee: Rubicon Research Private LimitedInventors: Pratibha Sudhir Pilgaonkar, Maharukh Tehmasp Rustomjee, Anilkumar Surendrakumar Gandhi, Pradnya Bagde, Varsha Barve
-
Patent number: 8920837Abstract: The novel sustained release dosage form comprising an active agent and a combination of a non-swelling pH dependent release retardant and a non swelling pH independent release retardant polymer which provides pH-independent drug release for a considerable period of time after administration.Type: GrantFiled: July 3, 2006Date of Patent: December 30, 2014Assignee: Rubicon Research Private LimitedInventors: Pratibha S. Pilgaonkar, Maharukh T. Rustomjee, Anilkumar S. Gandhi, Paras R. Jain, Atul A. Kelkar
-
Publication number: 20140227202Abstract: The present invention relates to oral care compositions and to method of maintaining oral health. The oral care composition of the present invention comprises at least one carbon dioxide source, at least one acid source, at least one abrasive and one or more pharmaceutically acceptable excipients.Type: ApplicationFiled: September 28, 2012Publication date: August 14, 2014Applicant: RUBICON RESEARCH PRIVATE LIMITEDInventors: Pratibha Sudhir Pilgaonkar, Maharukh Tehmasp Rustomjee, Anilkumar Surendrakumar Gandhi
-
Publication number: 20130336945Abstract: The present invention relates to stable pharmaceutical compositions of tetrahydrobiopterin and processes for producing such compositions. Particularly the present invention relates to stable pharmaceutical compositions comprising tetrahydrobiopterin and at least one stabilizing agent.Type: ApplicationFiled: March 1, 2013Publication date: December 19, 2013Applicant: RUBICON RESEARCH PRIVATE LIMITEDInventors: Maharukh Tehmasp Rustomjee, Anilkumar Surendrakumar Gandhi
-
Patent number: 8545890Abstract: The present invention describes a directly compressible composite excipient prepared by coating calcium silicate with a carbohydrate. The present invention further describes the incorporation of the composite excipient into a tablet formulation. The orally disintegrating tablets are of optimal mechanical strength and disintegrate within 60 seconds in the oral cavity.Type: GrantFiled: November 14, 2008Date of Patent: October 1, 2013Assignee: Rubicon Research Private LimitedInventors: Pratibha Pilgaonkar, Maharukh Rustomjee, Anilkumar Gandhi, Pradnya M. Bagde
-
Publication number: 20130230587Abstract: Sustained release compositions comprising plurality of sustained release beads are disclosed. Particularly the sustained release beads comprise coated drug-resin complexes comprising drug-resin complexes of at least one active agent and at least one ion-exchange resin; coated with at least one release modifier.Type: ApplicationFiled: November 10, 2010Publication date: September 5, 2013Applicant: Rubicon Research Private LimitedInventors: Pratibha Sudhir Pilgaonkar, Maharukh Tehmasp Rustomjee, Anikumar Surendrakumar Gandhi
-
Publication number: 20130078290Abstract: The present invention relates to gastroretentive dosage forms of gamma aminobutyric acid (“GABA”) analogs, and to processes for preparation of the same. The present invention provides gastroretentive dosage forms comprising GABA analog, at least one swelling agent and at least one non-swelling release retardant.Type: ApplicationFiled: June 1, 2011Publication date: March 28, 2013Applicant: Rubicon Research Private LimitedInventors: Pratibha Sudhir Pilgaonkar, Maharukh Tehmasp Rustomjee, Anilkumar Surendrakumar Gandhi